Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic MalignanciesMohamed L. Sorror, Rainer Storb, Dietger Niederwieser et al.|JAMA|2011Cited by 320
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)Nicolaus Kröger, Théo de Witte, Guido Kobbe et al.|Journal of Clinical Oncology|2017Cited by 248
Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell TransplantationRainer Storb, Brenda M. Sandmaier, Michael A. Pulsipher et al.|Journal of Clinical Oncology|2013Cited by 212
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decadesJason P. Cooper, Brenda M. Sandmaier, H. Joachim Deeg et al.|Haematologica|2020Cited by 39